共 50 条
- [41] Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Im, Hyeon-SuKim, Kyu-PyoOh, Do-YounLee, Kyung-HunChon, Hong JaeKim, Joo HoonKang, Myoung JooKim, Il-HwanLee, Guk JinOh, Sung YongChoi, YounakChoi, Hye JinKim, Seung TaePark, Joon OhRyoo, Baek-Yeol
- [42] Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancerJOURNAL OF CHEMOTHERAPY, 2002, 14 (04) : 406 - 411Tsavaris, NKosmas, CGennatas, KVadiaka, MSkopelitis, EXila, VRokana, SMargaris, EZografos, GPapastratis, GKouraklis, G
- [43] Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/IN in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Chen, Li-TzongSiveke, Jens T.Wang-Gillam, AndreaHubner, RichardPant, ShubhamDragovich, TomislavChung, Vincent M.Chang, David Z.Ross, Paul J.Cooray, PrasadTebbutt, Niall C.Franke, Fabio A.Belanger, BruceDhindsa, Navreetde Jong, FlorisMamlouk, KhalidVon Hoff, Daniel D.
- [44] A phase II experience with neoadjuvant irinotecan (CPT-II), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastasesBMC CANCER, 2009, 9Bathe, Oliver F.Ernst, ScottSutherland, Francis R.Dixon, ElijahButts, CharlesBigam, DavidHolland, DavidPorter, Geoffrey A.Koppel, JenniferDowden, Scot
- [45] A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastasesBMC Cancer, 9Oliver F BatheScott ErnstFrancis R SutherlandElijah DixonCharles ButtsDavid BigamDavid HollandGeoffrey A PorterJennifer KoppelScot Dowden
- [46] Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Yoo, ChanghoonKim, Kyu-PyoKim, IlhwanKang, Myoung JooCheon, JaekyungKang, Byung WoogRyu, HyewonJeong, Jae HoLee, Ji SungKim, Kyung WonRyoo, Baek-Yeol
- [47] Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC)ANNALS OF ONCOLOGY, 2022, 33 (07) : S565 - S565Yoo, C.Kim, K-P.Kim, I.Kang, M. J.Cheon, J.Kang, B. W.Ryu, H.Jeong, J.Lee, J. S.Kim, K. W.Ryoo, B-Y.Abou-Alfa, G. K.
- [48] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Pelzer, UweBlanc, Jean-FredericMelisi, DavideCubillo, AntonioVon Hoff, Daniel D.Wang-Gillam, AndreaChen, Li-TzongSiveke, Jens T.Wan, YinSolem, Caitlyn T.Botteman, MarcYang, Yoojungde Jong, FlorisHubner, Richard
- [49] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinomaCancer Chemotherapy and Pharmacology, 2010, 66 : 559 - 566Fotios LoupakisGianluca MasiLorenzo FornaroEnrico VasileGiacomo AllegriniEloise FontanaCristina GranettoLisa SalvatoreLucia MentucciaMichele AndreuccettiEnrico CortesiMarco MerlanoStefano CascinuAlfredo Falcone
- [50] Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trialANNALS OF ONCOLOGY, 2018, 29Macarulla Mercade, T.Lee, K.Lakatos, G.Wang-Gillam, A.Chen, L.Mirakhur, B.De Jong, F.